|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
2
|
Zhang X, Wang Y and Meng L: Comparative
genomic analysis of esophageal squamous cell carcinoma and
adenocarcinoma: New opportunities towards molecularly targeted
therapy. Acta Pharm Sin B. 12:1054–1067. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rubenstein JH and Shaheen NJ:
Epidemiology, diagnosis, and management of esophageal
adenocarcinoma. Gastroenterology. 149:302–317.e1. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xia C, Dong X, Li H, Cao M, Sun D, He S,
Yang F, Yan X, Zhang S, Li N and Chen W: Cancer statistics in China
and United States, 2022: Profiles, trends, and determinants. Chin
Med J (Engl). 135:584–590. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mansour NM, Groth SS and Anandasabapathy
S: Esophageal adenocarcinoma: Screening, surveillance, and
management. Annu Rev Med. 68:213–227. 2017. View Article : Google Scholar
|
|
6
|
Acharya R, Mahapatra A, Verma HK and
Bhaskar LVKS: Unveiling therapeutic targets for esophageal cancer:
A comprehensive review. Curr Oncol. 30:9542–9568. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
He S, Xu J, Liu X and Zhen Y: Advances and
challenges in the treatment of esophageal cancer. Acta Pharm Sin B.
11:3379–3392. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fatehi Hassanabad A, Chehade R, Breadner D
and Raphael J: Esophageal carcinoma: Towards targeted therapies.
Cell Oncol. 43:195–209. 2020. View Article : Google Scholar
|
|
9
|
Liu K, Zhao T, Wang J, Chen Y, Zhang R,
Lan X and Que J: Etiology, cancer stem cells and potential
diagnostic biomarkers for esophageal cancer. Cancer Lett.
458:21–28. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Luan S, Zeng X, Zhang C, Qiu J, Yang Y,
Mao C, Xiao X, Zhou J, Zhang Y and Yuan Y: Advances in Drug
Resistance of Esophageal Cancer: From the perspective of tumor
microenvironment. Front Cell Dev Biol. 9:6648162021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ye C, Yan X and Gao Y: Advances in
epigenetic therapy for esophageal cancer. Clin Epigenetics.
18:422026. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Recillas-Targa F: Cancer epigenetics: An
overview. Arch Med Res. 53:732–740. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
He PC and He C: m6A RNA methylation: From
mechanisms to therapeutic potential. EMBO J. 40:e1059772021.
View Article : Google Scholar
|
|
14
|
Jain S, Koziej L, Poulis P, Kaczmarczyk I,
Gaik M, Rawski M, Ranjan N, Glatt S and Rodnina MV: Modulation of
translational decoding by m6A modification of mRNA. Nat Commun.
14:47842023. View Article : Google Scholar
|
|
15
|
Zhang H, Shi X, Huang T, Zhao X, Chen W,
Gu N and Zhang R: Dynamic landscape and evolution of m6A
methylation in human. Nucleic Acids Res. 48:6251–6264. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Han SH and Choe J: Diverse molecular
functions of m6A mRNA modification in cancer. Exp Mol Med.
52:738–749. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hong J, Xu K and Lee JH: Biological roles
of the RNA m6A modification and its implications in cancer. Exp Mol
Med. 54:1822–1832. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Quan C, Belaydi O, Hu J, Li H, Yu A, Liu
P, Yi Z, Qiu D, Ren W, Ma H, et al: N6-Methyladenosine in cancer
immunotherapy: An undervalued therapeutic target. Front Immunol.
12:6970262021. View Article : Google Scholar
|
|
19
|
Brewer G: METTL3 inhibition enhances
antitumour immunity. Nat Rev Cancer. 23:6542023. View Article : Google Scholar
|
|
20
|
Wang L, Yang Q, Zhou Q, Fang F, Lei K, Liu
Z, Zheng G, Zhu L, Huo J, Li X, et al: METTL3-m6A-EGFR-axis drives
lenvatinib resistance in hepatocellular carcinoma. Cancer Lett.
559:2161222023. View Article : Google Scholar
|
|
21
|
Deng X, Qing Y, Horne D, Huang H and Chen
J: The roles and implications of RNA m6A modification in cancer.
Nat Rev Clin Oncol. 20:507–526. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Y, Hong Z, Song J, Zhong P and Lin L:
METTL3 promotes drug resistance to oxaliplatin in gastric cancer
cells through DNA repair pathway. Front Pharmacol. 14:12574102023.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang Y, Quan M, Chen Q, Han H, Zhang X,
Xu X and Wang Z: Recent progress of METTL3 inhibitors for cancer
therapeutics: Design, optimization and potential applications. RSC
Med Chem. 17:1289–1298. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang X, Feng J, Xue Y, Guan Z, Zhang D,
Liu Z, Gong Z, Wang Q, Huang J, Tang C, et al: Structural basis of
N6-adenosine methylation by the METTL3-METTL14 complex. Nature.
534:575–578. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yu D, Horton JR, Yang J, Hajian T, Vedadi
M, Sagum CA, Bedford MT, Blumenthal RM, Zhang X and Cheng X: Human
MettL3-MettL14 RNA adenine methyltransferase complex is active on
double-stranded DNA containing lesions. Nucleic Acids Res.
49:11629–11642. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lin S, Choe J, Du P, Triboulet R and
Gregory RI: The m6A methyltransferase METTL3 promotes translation
in human cancer cells. Mol Cell. 62:335–345. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee JH, Hong J, Zhang Z, de la Peña Avalos
B, Proietti CJ, Deamicis AR, Guzmán GP, Lam HM, Garcia J, Roudier
MP, et al: Regulation of telomere homeostasis and genomic stability
in cancer by N6-adenosine methylation (m6A). Sci Adv.
7:eabg70732021. View Article : Google Scholar
|
|
28
|
Li Y, He X, Lu X, Gong Z, Li Q, Zhang L,
Yang R, Wu C, Huang J, Ding J, et al: METTL3 acetylation impedes
cancer metastasis via fine-tuning its nuclear and cytosolic
functions. Nat Commun. 13:63502022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zheng W, Dong X, Zhao Y, Wang S, Jiang H,
Zhang M, Zheng X and Gu M: Multiple functions and mechanisms
underlying the role of METTL3 in human cancers. Front Oncol.
9:014032019. View Article : Google Scholar
|
|
30
|
Xu J, Chen Q, Tian K, Liang R, Chen T,
Gong A, Mathy NW, Yu T and Chen X: m6A methyltransferase METTL3
maintains colon cancer tumorigenicity by suppressing SOCS2 to
promote cell proliferation. Oncol Rep. 44:973–986. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Peng K, Chen X, Lin A, Tong Z and Lin W:
PolyC-RNA-binding protein 1 (PCBP1) enhances tropomyosin 3 (TPM3)
mRNA stability to promote the progression of esophageal squamous
cell carcinoma. Bioengineered. 13:8581–8592. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Delaunay S and Frye M:
Localization-dictated function for METTL3. Nat Cell Biol.
24:1188–1189. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dai Z, Lin B, Qin M, Lin Y, Wang L, Liao
K, Xie G, Wang F and Zhang J: METTL3-mediated m6A modification of
SLC7A11 enhances nasopharyngeal carcinoma radioresistance by
inhibiting ferroptosis. Int J Biol Sci. 21:1837–1851. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mao W, Jiang Q, Feng Y, Peng C, Peng H, Li
X, Jiao L, Zhang L, Ma L and Sun T: TRIM21-mediated METTL3
degradation promotes PDAC ferroptosis and enhances the efficacy of
Anti-PD-1 immunotherapy. Cell Death Dis. 16:2402025. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chun H and Baima K: METTL3-driven m6A
modifications in esophageal squamous cell Carcinoma: Emerging
mechanisms, biomarker potential, and therapeutic innovations. Eur J
Pharmacol. 1002:1777852025. View Article : Google Scholar
|
|
36
|
Yang L, Ding C, Tuo M, Chu T and Liu P:
METTL3 enhances esophageal squamous cell carcinoma progression by
suppressing ferroptosis through the PBX3/CA9 cascade. Pathol Res
Pract. 269:1558652025. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liang X, Zhang Z, Wang L, Zhang S, Ren L,
Li S, Xu J and Lv S: Mechanism of methyltransferase like 3 in
epithelial-mesenchymal transition process, invasion, and metastasis
in esophageal cancer. Bioengineered. 12:10023–10036. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Han H, Yang C, Zhang S, Cheng M, Guo S,
Zhu Y, Ma J, Liang Y, Wang L, Zheng S, et al: METTL3-mediated m6A
mRNA modification promotes esophageal cancer initiation and
progression via Notch signaling pathway. Mol Ther Nucleic Acids.
26:333–346. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang H, Zhang Y, Chen L, Liu Y, Xu C,
Jiang D, Song Q, Wang H, Wang L, Lin Y, et al: Identification of
clinical prognostic features of esophageal cancer based on m6A
regulators. Front Immunol. 13:9503652022. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li J, Li Z, Xu Y, Huang C and Shan B:
METTL3 facilitates tumor progression by COL12A1/MAPK signaling
pathway in esophageal squamous cell carcinoma. J Cancer.
13:1972–1984. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li Y, Niu C, Wang N, Huang X, Cao S, Cui
S, Chen T, Huo X and Zhou R: The role of m6A Modification and m6A
regulators in esophageal cancer. Cancers (Basel). 14:51392022.
View Article : Google Scholar
|
|
42
|
Xia TL, Yan SM, Yuan L and Zeng MS:
Upregulation of METTL3 expression predicts poor prognosis in
patients with esophageal squamous cell carcinoma. Cancer Manag Res.
12:5729–5737. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhou Y, Guo S, Li Y, Chen F, Wu Y, Xiao Y
and An J: METTL3 is associated with the malignancy of esophageal
squamous cell carcinoma and serves as a potential immunotherapy
biomarker. Front Oncol. 12:8241902022. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen X, Huang L, Yang T, Xu J, Zhang C,
Deng Z, Yang X, Liu N, Chen S and Lin S: METTL3 promotes esophageal
squamous cell carcinoma metastasis through enhancing GLS2
expression. Front Oncol. 11:6674512021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu XS, Yuan LL, Gao Y, Zhou LM, Yang JW
and Pei ZJ: Overexpression of METTL3 associated with the metabolic
status on 18F-FDG PET/CT in patients with Esophageal Carcinoma. J
Cancer. 11:4851–4860. 2020. View Article : Google Scholar
|
|
46
|
Ge F, Li Z, Hu J, Pu Y, Zhao F and Kong L:
METTL3/m6A/IFIT2 regulates proliferation, invasion and immunity in
esophageal squamous cell carcinoma. Front Pharmacol.
13:10025652022. View Article : Google Scholar
|
|
47
|
Teng C, Kong F, Mo J, Lin W, Jin C, Wang K
and Wang Y: The roles of RNA N6-methyladenosine in esophageal
cancer. Heliyon. 8:e114302022. View Article : Google Scholar
|
|
48
|
Wang W, Shao F, Yang X, Wang J, Zhu R,
Yang Y, Zhao G, Guo D, Sun Y, Wang J, et al: METTL3 promotes tumour
development by decreasing APC expression mediated by APC mRNA
N6-methyladenosine-dependent YTHDF binding. Nat Commun.
12:38032021. View Article : Google Scholar
|
|
49
|
Chen Z, Li C, Zhou Y, Li P, Cao G, Qiao Y,
Yao Y and Su J: Histone 3 lysine 9 acetylation-specific
reprogramming regulates esophageal squamous cell carcinoma
progression and metastasis. Cancer Gene Ther. 31:612–626. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Jin Q, Qu H and Quan C: New insights into
the regulation of METTL3 and its role in tumors. Cell Commun
Signal. 21:3342023. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chen J, Zhu ZX, Yang PJ, Deng F, Li PF,
Zhu ZF, Xu X, Wu WJ and Shen WG: The dysregulation of UPP1 incurred
by METTL3 regulates the malignancy of esophageal squamous cell
carcinoma in an m6A-YTHDC1-KLF5-mediated manner. Cell Signal.
137:1122012026. View Article : Google Scholar
|
|
52
|
Ma R and Zhao L: The role and mechanism of
ferroptosis mediated by METTL3-m6A modification in regulating
radioresistance of esophageal cancer. Int J Radiat Oncol Biol Phys.
117:e248–e249. 2023. View Article : Google Scholar
|
|
53
|
Chen X, Zhang L, He Y, Huang S, Chen S,
Zhao W and Yu D: Regulation of m6A modification on ferroptosis and
its potential significance in radiosensitization. Cell Death
Discov. 9:3432023. View Article : Google Scholar
|
|
54
|
Ji P, Wan B, Gao M, Yin S, Wu H, Wang J,
Ma Y, Xu W and Wang M: METTL3 promotes esophageal squamous cell
carcinoma progression and reduces chemosensitivity to paclitaxel
through the CASP9/BIRC3-dependent apoptosis pathway. Genes Dis.
13:1016932025. View Article : Google Scholar :
|
|
55
|
Liu XS, Zhang Y, Liu ZY, Gao Y, Yuan LL,
Zeng DB, Tan F, Wan HB and Pei ZJ: METTL3 as a novel diagnosis and
treatment biomarker and its association with glycolysis,
cuproptosis and ceRNA in oesophageal carcinoma. J Cell Mol Med.
28:e181952024. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zou J, Zhong X, Zhou X, Xie Q, Zhao Z, Guo
X and Duan Y: The M6A methyltransferase METTL3 regulates
proliferation in esophageal squamous cell carcinoma. Biochem
Biophys Res Commun. 580:48–55. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Chen J, Li S, Huang Z, Cao C, Wang A and
He Q: METTL3 suppresses anlotinib sensitivity by regulating m6A
modification of FGFR3 in oral squamous cell carcinoma. Cancer Cell
Int. 22:2952022. View Article : Google Scholar
|
|
58
|
Huang T, You Q, Liu J, Shen X, Huang D,
Tao X, He Z, Wu C, Xi X, Yu S, et al: WTAP Mediated m6A
modification stabilizes PDIA3P1 and promotes tumor progression
driven by histone lactylation in esophageal squamous cell
carcinoma. Adv Sci (Weinh). 12:e065292025. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Liao L, He Y, Li SJ, Zhang GG, Yu W, Yang
J, Huang ZJ, Zheng CC, He QY, Li Y and Li B: Anti-HIV drug
elvitegravir suppresses cancer metastasis via increased proteasomal
degradation of m6A methyltransferase METTL3. Cancer Res.
82:2444–2457. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Qiu Y, Tian Z, Miao TY, Shen L, Chen J, Li
PF, Zhu ZX, Zhu ZF, Wu WJ, Xu X and Shen WG: The
METTL3-m6A-YTHDC1-AMIGO2 axis contributes to cell proliferation and
migration in esophageal squamous cell carcinoma. Gene.
908:1482812024. View Article : Google Scholar
|
|
61
|
Zhang X, Bai Y, Shang L, Wang Y, Yao W and
Wu S: METTL3-Mediated m6A Methylation Stabilizes IFI27 to drive
esophageal squamous cell carcinoma progression through an
IGF2BP2-Dependent Mechanism. J Biochem Mol Toxicol. 39:e701672025.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Zhang TT, Yi W, Dong DZ, Ren ZY, Zhang Y
and Du F: METTL3-mediated upregulation of FAM135B promotes EMT of
esophageal squamous cell carcinoma via regulating the Wnt/β-catenin
pathway. Am J Physiol Cell Physiol. 327:C329–C340. 2024. View Article : Google Scholar
|
|
63
|
Wang P, Chen S, Lei M, Chen Y, He H, Chen
P, Chen W, Zhou H, Wang F and Zhang D: METTL3-mediated m6A
methylation of LncRNA DUXAP8 promoted esophageal squamous cell
carcinoma progression by activating the PI3K/AKT signaling pathway.
Cell Div. 21:12025. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Hou H, Zhao H, Yu X, Cong P, Zhou Y, Jiang
Y and Cheng Y: METTL3 promotes the proliferation and invasion of
esophageal cancer cells partly through AKT signaling pathway.
Pathol Res Pract. 216:1530872020. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhang L, Cai E, Xu Y, Liu Z, Zheng M, Sun
Z, Pei D and Wang Q: YTHDF1 facilitates esophageal cancer
progression via augmenting m6A-dependent TINAGL1 translation. Cell
Signal. 122:1113322024. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Guo X, Huang A, Qi Y, Chen J, Yang M and
Jin M: METTL3/IGF2BP2 Promotes the Malignant Progression of
Esophageal Cancer by Activating the PIK3CA/AKT Pathway. Thorac
Cancer. 16:e700222025. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Han Y, Sun J, Yao M, Miao L and Li M:
Biological roles of enhancer RNA m6A modification and its
implications in cancer. Cell Commun Signal. 23:2542025. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Huang C, Zhang K, Guo Y, Shen C, Liu X,
Huang H, Dou X and Yu B: The crucial roles of m6A RNA
modifications in cutaneous cancers: Implications in pathogenesis,
metastasis, drug resistance, and targeted therapies. Genes Dis.
10:2320–2330. 2022. View Article : Google Scholar
|
|
69
|
Choe J, Lin S, Zhang W, Liu Q, Wang L,
Ramirez-Moya J, Du P, Kim W, Tang S, Sliz P, et al: mRNA
circularization by METTL3-eIF3h enhances translation and promotes
oncogenesis. Nature. 561:556–560. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Wei X, Huo Y, Pi J, Gao Y, Rao S, He M,
Wei Q, Song P, Chen Y, Lu D, et al: METTL3 preferentially enhances
non-m6A translation of epigenetic factors and promotes
tumourigenesis. Nat Cell Biol. 24:1278–1290. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Song Z, Wang X, Chen F, Chen Q, Liu W,
Yang X, Zhu X, Liu X and Wang P: LncRNA MALAT1 regulates
METTL3-mediated PD-L1 expression and immune infiltrates in
pancreatic cancer. Front Oncol. 12:10042122022. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Brichkina A, Suezov R and Huber M:
Methyltransferase-like 3 (METTL3) inhibition potentiates antitumor
immunity: A novel strategy for improving anti-PD1 therapy. Signal
Transduct Target Ther. 8:4482023. View Article : Google Scholar
|
|
73
|
Yu H, Liu J, Bu X, Ma Z, Yao Y, Li J,
Zhang T, Song W, Xiao X, Sun Y, et al: Targeting METTL3 reprograms
the tumor microenvironment to improve cancer immunotherapy. Cell
Chem Biol. 31:776–791.e7. 2024. View Article : Google Scholar
|
|
74
|
Peng L, Wang D, Han Y, Huang T, He X, Wang
J and Ou C: emerging role of cancer-associated fibroblasts-derived
exosomes in tumorigenesis. Front Immunol. 12:7953722022. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Sun Y, Shen W, Hu S, Lyu Q, Wang Q, Wei T,
Zhu W and Zhang J: METTL3 promotes chemoresistance in small cell
lung cancer by inducing mitophagy. J Exp Clin Cancer Res.
42:652023. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Hu F, Zhang S and Chai J: METTL3 promotes
gastric cancer progression via modulation of FNTA-Mediated KRAS/ERK
signaling activation. Mol Cancer Res. 23:724–738. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Hwang K, Bae J, Jhe YL, Kim J, Cheong JH,
Choi HS and Sim T: Targeted degradation of METTL3 against acute
myeloid leukemia and gastric cancer. Eur J Med Chem.
279:1168432024. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Zhang L, Mao Z, Yin K and Wang S: Review
of METTL3 in colorectal cancer: From mechanisms to the therapeutic
potential. Int J Biol Macromol. 277:1342122024. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Li B, Hong P, Zheng CC, Dai W, Chen WY,
Yang QS, Han L, Tsao SW, Chan KT, Lee NPY, et al: Identification of
miR-29c and its Target FBXO31 as a key regulatory mechanism in
esophageal cancer chemoresistance: Functional validation and
clinical significance. Theranostics. 9:1599–1613. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Zhang HF, Wu C, Alshareef A, Gupta N, Zhao
Q, Xu XE, Jiao JW, Li EM, Xu LY and Lai R: The PI3K/AKT/c-MYC axis
promotes the acquisition of cancer stem-like features in esophageal
squamous cell carcinoma. Stem Cells. 34:2040–2051. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Liao X, Cai D, Liu J, Hu H, You R, Pan Z,
Chen S, Xu K, Dai W, Zhang S, et al: Deletion of Mettl3 in
mesenchymal stem cells promotes acute myeloid leukemia resistance
to chemotherapy. Cell Death Dis. 14:7962023. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Li M, Xia M, Zhang Z, Tan Y, Li E, Guo Z,
Fang M, Zhu Y and Hu Z: METTL3 antagonizes 5-FU chemotherapy and
confers drug resistance in colorectal carcinoma. Int J Oncol.
61:1062022. View Article : Google Scholar
|
|
83
|
He X, Li Y, Li J, Li Y, Chen S, Yan X, Xie
Z, Du J, Chen G, Song J and Mei Q: HDAC2-Mediated METTL3
delactylation promotes DNA damage repair and chemotherapy
resistance in triple-negative breast cancer. Adv Sci (Weinh).
12:e24131212025. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Li N, Wei X, Dai J, Yang J and Xiong S:
METTL3: A multifunctional regulator in diseases. Mol Cell Biochem.
480:3429–3454. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Puhr HC, Prager GW and Ilhan-Mutlu A: How
we treat esophageal squamous cell carcinoma. ESMO Open.
8:1007892023. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Korpan M, Puhr HC, Prager GW and
Ilhan-Mutlu A: State-of-the-art therapy and innovative treatment
strategies in esophageal squamous cell cancer. Memo. 17:274–279.
2024. View Article : Google Scholar
|
|
87
|
Sun X, Bai C, Li H, Xie D, Chen S, Han Y,
Luo J, Li Y, Ye Y, Jia J, et al: PARP1 modulates METTL3 promoter
chromatin accessibility and associated LPAR5 RNA m6A methylation to
control cancer cell radiosensitivity. Mol Ther. 31:2633–2650. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Zhang C, Yang T, Chen H, Ding X, Chen H,
Liang Z, Zhao Y, Ma S and Liu X: METTL3 inhibition promotes
radiosensitivity in hepatocellular carcinoma through regulation of
SLC7A11 expression. Cell Death Dis. 16:92025. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Shi X, Zhang X, Huang X, Zhang R, Pan S,
Huang S, Wang Y, Ke Y, Guo W, Liu X, et al:
N6-methyladenosine-mediated upregulation of LNCAROD confers
radioresistance in esophageal squamous cell carcinoma through
stabilizing PARP1. Clin Transl Med. 14:e700392024. View Article : Google Scholar
|
|
90
|
Sun H, Liu F, Song X, Sun R, Zhang M,
Huang J, Gu W and Shao Y: m6A-modified circCREBBP enhances
radiosensitivity of esophageal squamous cell carcinoma by reducing
the stability of MYC through interaction with IGF2BP3. Int J Biol
Macromol. 286:1385342025. View Article : Google Scholar
|
|
91
|
Gao C, Yang H, Cheng J, He S, Yang Y, Xu
L, Ma Q, Guo X and Zhong X: STM2457 impairs the proliferation of
esophageal squamous cell carcinoma by activating DNA damage
response through ATM-Chk2 axis. Med Oncol. 42:822025. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Bian Y, Bi G, Shan G, Liang J, Yao G, Sui
Q, Hu Z, Zhan C, Chen Z and Wang Q: Identification of the
relationship between single-cell N6-methyladenosine regulators and
the infiltrating immune cells in esophageal carcinoma. Heliyon.
9:e181322023. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Gong Y, Wu J and Hu Y: m6A
epitranscriptomic regulation of KRAS by METTL3 promotes EMT and
stromal remodeling through TGF-β/SMAD signaling in cervical cancer.
Cancer Gene Ther. 33:198–211. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN,
Chen ZH, Zeng ZL, Wang F, Zheng J, et al: METTL3 facilitates tumor
progression via an m6A-IGF2BP2-dependent mechanism in colorectal
carcinoma. Mol Cancer. 18:1122019. View Article : Google Scholar
|
|
95
|
Lin X, Hong Y, You S, Li P, Lv Y, Zheng J
and Sun P: METTL3-mediated m6A modification of LINC00857 enhances
stemness and metastasis of ovarian cancer cells by activating the
YAP-TEAD pathway. Sci Rep. 15:411322025. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Wu HX, Chen YK, Wang YN, Chen JY, Xiang
SJ, Jin Y, Wang ZX, Huang CY, Yang LP, He Y, et al: Dissecting
small cell carcinoma of the esophagus ecosystem by single-cell
transcriptomic analysis. Mol Cancer. 24:1422025. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Zhang X, Peng L, Luo Y, Zhang S, Pu Y,
Chen Y, Guo W, Yao J, Shao M, Fan W, et al: Dissecting esophageal
squamous-cell carcinoma ecosystem by single-cell transcriptomic
analysis. Nat Commun. 12:52912021. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Jia Y, Zhang B, Zhang C, Kwong DL, Chang
Z, Li S, Wang Z, Han H, Li J, Zhong Y, et al: Single-cell
transcriptomic analysis of primary and metastatic tumor ecosystems
in esophageal squamous cell carcinoma. Adv Sci (Weinh).
10:e22045652023. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Li R, Huang B, Tian H and Sun Z: Immune
evasion in esophageal squamous cell cancer: From the perspective of
tumor microenvironment. Front Oncol. 12:10967172023. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Guo W, Tan F, Huai Q, Wang Z, Shao F,
Zhang G, Yang Z, Li R, Xue Q, Gao S and He J: Comprehensive
Analysis of PD-L1 expression, immune infiltrates, and m6A RNA
methylation regulators in esophageal squamous cell carcinoma. Front
Immunol. 12:6697502021. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Sun Y and Huang S: METTL3-mediated m6A
modification of CXCR4 drives M2 macrophage polarization and
suppresses antitumor immunity in esophageal cancer. J Clin Biochem
Nutr. 78:136–141. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Yuan F, Zhang W, Xia Y, Zhou X and Gao H:
The role and mechanism of METTL3 in cancer: Emerging insights into
m6A methylation and therapeutic potential. Eur J Med Res.
30:10172025. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Fiorentino F, Menna M, Rotili D, Valente S
and Mai A: METTL3 from target validation to the first
small-molecule inhibitors: A medicinal chemistry journey. J Med
Chem. 66:1654–1677. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Tang H, Zhang R and Zhang A:
Small-molecule inhibitors targeting RNA m6A modifiers for cancer
therapeutics: Latest advances and future perspectives. J Med Chem.
68:18114–18142. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Moroz-Omori EV, Huang D, Kumar Bedi R,
Cheriyamkunnel SJ, Bochenkova E, Dolbois A, Rzeczkowski MD, Li Y,
Wiedmer L and Caflisch A: METTL3 inhibitors for epitranscriptomic
modulation of cellular processes. ChemMedChem. 16:3035–3043. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Moser JC, Papadopoulos KP, Rodon Ahnert J,
Ofir-Rosenfeld Y and Holz J-B; null n: Phase 1 dose escalation and
cohort expansion study evaluating safety, PK, PD and clinical
activity of STC-15, a METTL-3 inhibitor, in patients with advanced
malignancies. J Clin Oncol. 42:2586. 2024. View Article : Google Scholar
|
|
107
|
Bennett CF: Therapeutic antisense
oligonucleotides are coming of age. Annu Rev Med. 70:307–321. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Collotta D, Bertocchi I, Chiapello E and
Collino M: Antisense oligonucleotides: A novel Frontier in
pharmacological strategy. Front Pharmacol. 14:13043422023.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Wen L, Fu J, Wang Z, Xie R, Tang S, Yu L
and Zhou H: Regulatory mechanisms of m6A RNA methylation in
esophageal cancer: A comprehensive review. Front Genet.
16:15317992025. View Article : Google Scholar
|
|
110
|
Du W, Huang Y, Chen X, Deng Y, Sun Y, Yang
H, Shi Q, Wu F, Liu G, Huang H, et al: Discovery of a PROTAC
degrader for METTL3-METTL14 complex. Cell Chem Biol.
31:177–183.e17. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Dai XJ, Ji SK, Fu MJ, Liu GZ, Liu HM, Wang
SP, Shen L, Wang N, Herdewijn P, Zheng YC, et al: Degraders in
epigenetic therapy: PROTACs and beyond. Theranostics. 14:1464–1499.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Esteva-Socias M and Aguilo F: METTL3 as a
master regulator of translation in cancer: Mechanisms and
implications. NAR Cancer. 6:zcae0092024. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Nar R, Wu Z, Li Y, Smith A, Zhang Y, Wang
J, Yu F, Gao S, Yu C, Huo Z, et al: Targeting METTL3 protein by
proteolysis-targeting chimeras: A novel therapeutic approach for
acute myeloid leukemia. Genes Dis. 12:1014522024. View Article : Google Scholar
|
|
114
|
Smith AR, Nar R, Li Y, Gour A, Sharma A,
Qian Z, Zheng G and Wu Z: Discovery of CRBN-recruiting PROTAC
degraders of the METTL3-METTL14 complex. Med Chem Res.
34:2299–2308. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Li Z, Zheng C, Huang L, Yin X, Wang Z, Liu
C and Li B: The landscape of m6A regulators in esophageal cancer:
molecular characteristics, immuno-oncology features, and clinical
relevance. Ann Transl Med. 10:13472022. View Article : Google Scholar
|
|
116
|
Lyu Q, Chai Y, Chen W, Chen Y and Li Y:
Integrated bioinformatics analysis of differences between EAC and
ESCC. BMC Cancer. 25:16682025. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Yin F, Hernandez Gonzalo D, Lai J and Liu
X: Histopathology of barrett's esophagus and early-stage esophageal
adenocarcinoma: An updated review. Gastrointest Disord. 1:147–163.
2019. View Article : Google Scholar
|
|
118
|
Grady WM, Yu M, Markowitz SD and Chak A:
Barrett's esophagus and esophageal adenocarcinoma biomarkers.
Cancer Epidemiol Biomarkers Prev. 29:2486–2494. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Maslenkina K, Mikhaleva L, Naumenko M,
Vandysheva R, Gushchin M, Atiakshin D, Buchwalow I and Tiemann M:
Signaling pathways in the pathogenesis of barrett's esophagus and
esophageal adenocarcinoma. Int J Mol Sci. 24:93042023. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Zou K, Dong H, Li M, Zhang Y, Zhang K,
Song D and Chu C: Comprehensive analysis of transcriptome-wide
N6-methyladenosine methylomes in the Barrett's esophagus in rats.
Genomics. 115:1106872023. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Dilworth MP, Nieto T, Stockton JD, Whalley
CM, Tee L, James JD, Noble F, Underwood TJ, Hallissey MT, Hejmadi
R, et al: Whole Genome Methylation Analysis of Nondysplastic
Barrett Esophagus that Progresses to Invasive Cancer. Ann Surg.
269:479–485. 2019. View Article : Google Scholar :
|
|
122
|
Martinez-Uribe O, Becker TC and Garman KS:
Promises and limitations of current models for understanding
Barrett's Esophagus and esophageal adenocarcinoma. Cell Mol
Gastroenterol Hepatol. 17:1025–1038. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Boonstra JJ, van der Velden AW, Beerens
EC, van Marion R, Morita-Fujimura Y, Matsui Y, Nishihira T,
Tselepis C, Hainaut P, Lowe AW, et al: Mistaken identity of widely
used esophageal adenocarcinoma Cell Line TE-7. Cancer Res.
67:7996–8001. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Capes-Davis A, Theodosopoulos G, Atkin I,
Drexler HG, Kohara A, MacLeod RA, Masters JR, Nakamura Y, Reid YA,
Reddel RR and Freshney RI: Check your cultures! A list of
cross-contaminated or misidentified cell lines. Int J Cancer.
127:1–8. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Hu L, Liu S, Peng Y, Ge R, Su R,
Senevirathne C, Harada BT, Dai Q, Wei J, Zhang L, et al: m(6)A RNA
modifications are measured at single-base resolution across the
mammalian transcriptome. Nat Biotechnol. 40:1210–1219. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Johnson A, Ali SM, Yelensky R, Chmielecki
J, Elvin JA, Lipson D, Miller VA, Stephens PJ, Ross JS and Wang K:
Comprehensive genomic profiling of advanced stage esophageal
squamous cell carcinomas (ESCC) and esophageal adenocarcinomas
(EAC). J Clin Oncol. 33:1535. 2015. View Article : Google Scholar
|
|
127
|
Zheng G, Bi J, Yan Y, Yu B and Fu Y:
Emerging role of RNA m6A modifications in laryngeal squamous cell
carcinoma: Insights into tumorigenesis and therapeutic potential.
Apoptosis. 30:2077–2089. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Huang M, Wang X, Zhang M, Liu Y and Chen
YG: METTL3 restricts RIPK1-dependent cell death via the ATF3-cFLIP
axis in the intestinal epithelium. Cell Regen. 13:142024.
View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Kansal R, Sharma V, Potraje P and Datta M:
m6A RNA modification and its emerging roles in diseases: Recent
advances and therapeutic implications. J Transl Med. 24:4332026.
View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Errani F, Invernizzi A, Herok M,
Bochenkova E, Stamm F, Corbeski I, Romanucci V, Di Fabio G, Zálešák
F and Caflisch A: Proteolysis Targeting Chimera Degraders of the
METTL3-14 m6A-RNA Methyltransferase. JACS Au. 4:713–729.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Xing L, Jiang Z, Xu R, Dang T, Wu J, Chai
J and Meng X: CCN1 promotes APRIL/BAFF signaling in esophageal
squamous cell carcinoma but attenuates it in esophageal
adenocarcinoma. Sci Rep. 15:18082025. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Wu H, Yu J, Li Y, Hou Q, Zhou R, Zhang N,
Jing Z, Jiang M, Li Z, Hua Y, et al: Single-cell RNA sequencing
reveals diverse intratumoral heterogeneities and gene signatures of
two types of esophageal cancers. Cancer Lett. 438:133–143. 2018.
View Article : Google Scholar
|
|
133
|
Liu M, Huang Y, Tian H, Guo C, Liu Z, Liu
A, Yang H, Li F, Duan L, Shen L, et al: Absolute Risk Prediction
for Esophageal Squamous Cell Carcinoma Adaptable to Regional
Disease Burden across Diverse Regions. Cancer Epidemiol Biomarkers
Prev. 34:510–517. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Su W, Che L, Liao W and Huang H: The RNA
m6A writer METTL3 in tumor microenvironment: Emerging
roles and therapeutic implications. Front Immunol. 15:13357742024.
View Article : Google Scholar
|
|
135
|
Gu Y, Fang Y, Wu X, Xu T, Hu T, Xu Y, Ma
P, Wang Q and Shu Y: The emerging roles of SUMOylation in the tumor
microenvironment and therapeutic implications. Exp Hematol Oncol.
12:582023. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Li L, Jiang D, Zhang Q, Liu H, Xu F, Guo
C, Qin Z, Wang H, Feng J, Liu Y, et al: Integrative proteogenomic
characterization of early esophageal cancer. Nat Commun.
14:16662023. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Pei X, Liu Z, Tang L, Zhang J, He Y,
Zhuang X, Song Y, Peng S, He Y, Zhao Y, et al: Single-cell
multi-omic and spatial profiling of esophageal squamous cell
carcinoma reveals the immunosuppressive role of GPR116+ pericytes
in cancer metastasis. Nat Genet. 57:2494–2508. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Sinha UK, Park YM and Lin DC: A high-power
spatial, single-cell view of pericytes in esophageal cancer
metastasis. Nat Genet. 57:2350–2351. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Li G, Chen W, Liu D and Tang S: Recent
advances in medicinal chemistry strategies for the development of
METTL3 inhibitors. Eur J Med Chem. 290:1175602025. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Li H, Zhang Q, Feng Q, You Q and Guo X:
The development of small molecules targeting methyltransferase-like
3. Drug Discov Today. 28:1035132023. View Article : Google Scholar : PubMed/NCBI
|
